Creative Biolabs isolates B. dentium from complex matrices such as human or animal feces, intestinal contents, and oral samples under stringent anaerobic workflows. High-throughput screening pinpoints B. dentium strains with robust colonization, mucus adhesion, metabolite production, and acid tolerance profiles that align with your microbiome intervention strategy.
For precise identification, B. dentium isolates undergo polyphasic characterization, combining 16S rRNA sequencing, species-specific qPCR, MALDI-TOF profiling, and whole-genome sequencing where required. This multi-layered approach resolves closely related bifidobacterial species and links B. dentium genotypes to functional traits relevant for downstream mechanistic and safety studies.
B. dentium is adapted to utilize diverse dietary and host-derived glycans. Creative Biolabs systematically maps carbohydrate fermentative profiles of B. dentium strains using defined substrates (e.g., raffinose, XOS, mannitol, fucosyllactose), quantifying growth, acidification, and metabolite output to inform prebiotic pairing, synbiotic design, and colonization support strategies.
To support B. dentium–based product development, safety testing includes hemolysis assessment, biogenic amine production, antibiotic resistance gene screening, mobile element analysis, and in vitro cytotoxicity assays. Integrated genomic and phenotypic data help classify B. dentium strains against internal safety criteria and align with regulatory expectations for live biotherapeutic research pipelines.
Creative Biolabs conducts antimicrobial susceptibility testing on B. dentium using standardized MIC assays under anaerobic conditions. Panels typically include clinically relevant antibiotics and microbiome-relevant agents, enabling evaluation of intrinsic versus acquired resistance and informing risk assessments on horizontal gene transfer and potential interactions with concomitant antimicrobial exposure.
Functional and mechanism-of-action screening for B. dentium integrates mucus-layer models, epithelial cell lines, and neuronal or enteroendocrine readouts. Assays quantify GABA generation, serotonin modulation, mucin expression, ER stress markers, and cytokine profiles to construct a mechanistic map linking B. dentium activity to barrier integrity, visceral sensitivity, and gut–brain signaling.
Dedicated host–microbe interaction platforms measure how B. dentium adheres to mucus, interacts with epithelial junctions, and shapes goblet cell function. Co-culture and organoid systems capture strain-dependent effects on MUC2 secretion, autophagy pathways, and epithelial transcriptional programs, supporting rational strain selection and dose-setting in preclinical models.
In vitro immunomodulation assays quantify how B. dentium or its metabolites influence innate and adaptive immune readouts. Co-culture with dendritic cells, macrophages, or PBMCs reveals effects on cytokine balance, T-cell polarization, and regulatory pathways, informing hypotheses around immune tolerance, inflammation resolution, and systemic metabolite-driven signaling.
